Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
about
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosisMutant prevention concentration as a measure of fluoroquinolone potency against mycobacteriaDetermination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and ValnemulinDual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Drug interactions and the evolution of antibiotic resistance.Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesisConcentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistanceMechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsMutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.The role of RamA on the development of ciprofloxacin resistance in Salmonella enterica serovar Typhimurium.Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBContribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.Selective advantage of resistant strains at trace levels of antibiotics: a simple and ultrasensitive color test for detection of antibiotics and genotoxic agents.Activity of and resistance to moxifloxacin in Staphylococcus aureus.Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureusPrevention strategies for antimicrobial resistance: a systematic review of the literature.Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistanceFluoroquinolone Resistance in Salmonella and the Utility of Pefloxacin Disk Diffusion [corrected].In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin.A drug-eluting contact lensPervasive selection for and against antibiotic resistance in inhomogeneous multistress environmentsSuppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.Drug interactions modulate the potential for evolution of resistance.A unified anti-mutant dosing strategy.CD101: a novel long-acting echinocandin.Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV.Quinolones: action and resistance updated.Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium.Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.Implications of amino acid substitutions in GyrA at position 83 in terms of oxolinic acid resistance in field isolates of Burkholderia glumae, a causal agent of bacterial seedling rot and grain rot of rice.
P2860
Q28344614-696C8188-97EA-43E2-988C-80326F5A5AE9Q28344939-81C2F62E-2C08-4F5E-94C8-9294728522A0Q28468397-2AAA0D5B-7CA8-499B-A3A5-EFBEB10AB20AQ33770013-EEA0AEB7-CA92-404F-9319-C123CA02E46DQ33792926-23324852-6465-4793-89EB-246F6F4FF617Q33980255-EE9CA5ED-1A7C-4168-823B-0338509CDA89Q33980535-3F880125-E34D-4591-A7E3-C731B25380FCQ33980991-030806F9-379E-47AA-BDD0-C28377F9AEDAQ33981343-3EF2A66D-9E92-4F02-AD33-36AC44FBA867Q33981554-E013FD3D-46BF-4173-905B-ACAA009D8FEAQ33983092-87313E93-0A10-43A3-ACA3-52EF8FD4F186Q33999695-4D00935A-7011-45F7-90ED-64EA88FBAD45Q34077142-72AC850D-8D22-40E0-807E-598877F82144Q34228402-A5258E49-1722-40DD-BA2D-B3531B01525FQ34591451-52394FD9-EA9D-4402-BA8B-E1917E3D27AAQ34721556-4AAC630A-8404-4146-9889-95C0369AAB35Q34737391-1252A2B9-B1F6-48B8-AE92-531D29B0BEBCQ34885313-BFEC97F2-7508-4092-816D-DC7AC83882D8Q34932274-FD5B8885-67EC-468B-8B50-92A6449A9BB9Q35026563-70535197-A6F3-484F-AEA6-C4C53A305D13Q36086509-071AA852-B519-48E0-BC19-06EB32CBCD60Q36173899-45810917-986D-48CF-B957-79D691E168D6Q36187937-C2993663-BDC2-40B9-8E2B-21C496BB2A1DQ36311472-90F48892-959D-4728-B2F7-AF55AFB4F684Q36528302-7A2BE894-C18D-4348-A627-9080DA7755C9Q36817994-64DEF45F-4F01-422B-B035-2F5413F3CA0DQ36937085-35BF2C5B-B984-4185-9A29-D0938943D5BCQ37188136-395CC0A3-32BE-4DCE-9F07-A741C276EE35Q37394523-B5CEEFD0-8341-497D-8FED-B352520E323EQ37488787-B0DC015A-305A-4E7E-91E1-B23437CCC686Q37595559-3D52B163-C212-41A1-9A81-5B3D149474DAQ37624733-BE82E9CF-60EC-44B3-A9A1-FE8632A957A8Q37733449-F95FFAF2-C169-4C13-8CC6-AD9579BB1D5DQ39472413-261C9442-F6D8-46AC-863A-B3FFC7A5E0B8Q39477342-784EE638-9F61-465C-99F6-D8E058762A7FQ39478440-311276EA-5D7D-404D-8684-0F94386302D3Q39651272-B65838F5-7A39-49B3-B445-A142B022FA29Q39731893-F6CB179C-7CF7-44CE-B95D-70B365607631Q39792565-F8D2B474-9421-47DC-923A-3CDCBD5F213EQ40130101-D734FE67-1358-412E-87EF-4CA19DADB063
P2860
Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@ast
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@en
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@nl
type
label
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@ast
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@en
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@nl
prefLabel
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@ast
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@en
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@nl
P2093
P2860
P3181
P1476
Effect of fluoroquinolone conc ...... BCG and Staphylococcus aureus
@en
P2093
P2860
P304
P3181
P407
P577
1999-07-01T00:00:00Z